Abstract: An autonomous power regulation method enhances quality of the received signal under severe conditions such as weak signal, unbalanced power among antennas, and not identical power among subcarriers. The improvement in signal quality also means the better performance of the physical uplink control channel format two in the fifth generation mobile network. In terms of antenna index, symbol index, and subcarrier type, power of the received signal is autonomously compensated as the following four steps: step 1: sequence generation and reference calculation; step 2: signal extraction and magnitude calculation; step 3: threshold generation, gain calculation, and power regulation; step 4: channel estimation, channel equalization, channel decoder, and statistics. With various types of the received signal power level and wide range of signal-to-noise ratio, the provided experiment results prove that the autonomous power regulation method is effective, reliable, and versatile.

Abstract: The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compounds according to present invention have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.

Abstract: The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition containing the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compound has an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.

Abstract: The present invention relates to the use of diaryl hepatonoid-based compounds of formula (1) for inhibiting viral activity. The diaryl hepatonoid-based compounds have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.

Abstract: The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compounds according to present invention have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.

Abstract: The present invention relates to the use of triterpenoid-based compounds of formula (1) for inhibiting viral activity. The triterpenoid-based compounds have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.